JP2016536286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536286A5 JP2016536286A5 JP2016521347A JP2016521347A JP2016536286A5 JP 2016536286 A5 JP2016536286 A5 JP 2016536286A5 JP 2016521347 A JP2016521347 A JP 2016521347A JP 2016521347 A JP2016521347 A JP 2016521347A JP 2016536286 A5 JP2016536286 A5 JP 2016536286A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- formula
- hdac6
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 25
- 239000011780 sodium chloride Substances 0.000 claims 25
- 230000002401 inhibitory effect Effects 0.000 claims 20
- 102000011427 Histone Deacetylase 6 Human genes 0.000 claims 19
- 108010023925 Histone Deacetylase 6 Proteins 0.000 claims 19
- 239000003112 inhibitor Substances 0.000 claims 19
- 150000001875 compounds Chemical group 0.000 claims 17
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 102000003964 Histone deacetylases Human genes 0.000 claims 4
- 108090000353 Histone deacetylases Proteins 0.000 claims 4
- 125000005418 aryl aryl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 101710042656 BQ2027_MB1231C Proteins 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one Chemical group C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 claims 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N Idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims 1
- 229960003445 Idelalisib Drugs 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000004709 cell invasion Effects 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- -1 each of which is OH Chemical group 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 claims 1
- 0 *N(CCCCCCC(NO)=O)C(c1cnc(N(*)C2=CC=CC=CC2)nc1)=O Chemical compound *N(CCCCCCC(NO)=O)C(c1cnc(N(*)C2=CC=CC=CC2)nc1)=O 0.000 description 3
- VLIUIBXPEDFJRF-UHFFFAOYSA-N ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)=O)=O Chemical compound ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)=O)=O VLIUIBXPEDFJRF-UHFFFAOYSA-N 0.000 description 2
- QGZYDVAGYRLSKP-UHFFFAOYSA-N ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c2ccccc2)nc1)=O)=O Chemical compound ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c2ccccc2)nc1)=O)=O QGZYDVAGYRLSKP-UHFFFAOYSA-N 0.000 description 2
- LIIWIMDSZVNYHY-UHFFFAOYSA-N ONC(c1cnc(NC2(CC2)c2ccccc2)nc1)=O Chemical compound ONC(c1cnc(NC2(CC2)c2ccccc2)nc1)=O LIIWIMDSZVNYHY-UHFFFAOYSA-N 0.000 description 2
- IYBURCQQEUNLDL-UHFFFAOYSA-N ONC(c1cnc(NC2(CCCCC2)c2cccc(F)c2)nc1)=O Chemical compound ONC(c1cnc(NC2(CCCCC2)c2cccc(F)c2)nc1)=O IYBURCQQEUNLDL-UHFFFAOYSA-N 0.000 description 2
- PQDKJKQGRALNHS-QZQOTICOSA-N CCC/C(/C(NCCCCCCC(NO)=O)=O)=C\N=C(/N)\N(c1ccccc1)c1ccccc1 Chemical compound CCC/C(/C(NCCCCCCC(NO)=O)=O)=C\N=C(/N)\N(c1ccccc1)c1ccccc1 PQDKJKQGRALNHS-QZQOTICOSA-N 0.000 description 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361888207P | 2013-10-08 | 2013-10-08 | |
US61/888,207 | 2013-10-08 | ||
PCT/US2014/059238 WO2015054099A1 (en) | 2013-10-08 | 2014-10-06 | Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016536286A JP2016536286A (ja) | 2016-11-24 |
JP2016536286A5 true JP2016536286A5 (US20070167479A1-20070719-C00034.png) | 2017-11-16 |
JP6626437B2 JP6626437B2 (ja) | 2019-12-25 |
Family
ID=52777441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016521347A Active JP6626437B2 (ja) | 2013-10-08 | 2014-10-06 | ヒストンデアセチラーゼ阻害剤とHer2阻害剤またはPI3K阻害剤のいずれかの組み合わせ |
Country Status (5)
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010007418A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
TWI511732B (zh) | 2010-01-22 | 2015-12-11 | Acetylon Pharmaceuticals Inc | 作為蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法 |
CA2818125A1 (en) | 2010-11-16 | 2012-05-24 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
AR084824A1 (es) | 2011-01-10 | 2013-06-26 | Intellikine Inc | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas |
WO2013158984A1 (en) | 2012-04-19 | 2013-10-24 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
JP6626437B2 (ja) * | 2013-10-08 | 2019-12-25 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | ヒストンデアセチラーゼ阻害剤とHer2阻害剤またはPI3K阻害剤のいずれかの組み合わせ |
ES2862126T3 (es) * | 2013-10-10 | 2021-10-07 | Acetylon Pharmaceuticals Inc | Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa |
WO2015054355A1 (en) * | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma |
EP4137135B1 (en) | 2013-10-24 | 2024-06-05 | Mayo Foundation for Medical Education and Research | Treatment of polycystic diseases with an hdac6 inhibitor |
CR20160308A (es) | 2013-12-03 | 2016-11-08 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores |
GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
CN107205988A (zh) | 2014-07-07 | 2017-09-26 | 埃斯泰隆制药公司 | 利用组蛋白脱乙酰酶抑制剂治疗白血病 |
AU2015356779A1 (en) | 2014-12-05 | 2017-07-13 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma |
SG11201704759QA (en) | 2014-12-12 | 2017-07-28 | Regenacy Pharmaceuticals Llc | Piperidine derivatives as hdac1/2 inhibitors |
WO2016200919A1 (en) | 2015-06-08 | 2016-12-15 | Acetylon Pharmaceuticals, Inc. | Crystalline forms of a histone deacetylase inhibitor |
CN107922352B (zh) * | 2015-06-08 | 2021-08-06 | 埃斯泰隆制药公司 | 制备蛋白质脱乙酰酶抑制剂的方法 |
GB201514756D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
US11813261B2 (en) | 2016-04-19 | 2023-11-14 | Acetylon Pharmaceuticals, Inc. | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia |
ES2973875T3 (es) * | 2016-06-09 | 2024-06-24 | Dana Farber Cancer Inst Inc | Métodos de uso y combinaciones farmacéuticas de inhibidores de HDAC con inhibidores de BET |
SG11201811237WA (en) | 2016-06-24 | 2019-01-30 | Infinity Pharmaceuticals Inc | Combination therapies |
US11324744B2 (en) | 2016-08-08 | 2022-05-10 | Acetylon Pharmaceuticals Inc. | Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies |
WO2018098168A1 (en) | 2016-11-23 | 2018-05-31 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereof |
WO2018237007A1 (en) * | 2017-06-22 | 2018-12-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR THE TREATMENT OF CANCER |
WO2019099353A1 (en) * | 2017-11-15 | 2019-05-23 | California State University Northridge | Compositions and methods for the treatment and prevention of cancer |
US11433069B2 (en) | 2017-12-01 | 2022-09-06 | University of Modena and Reggio Emilia | Methods of use and pharmaceutical combinations comprising histone deacetylase inhibitors and JAK1/2 inhibitors |
CA3144639A1 (en) * | 2019-06-21 | 2020-12-24 | Nidhi Singh | Therapeutic compositions and methods for treating cancers |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3549633A (en) | 1968-11-20 | 1970-12-22 | Merck & Co Inc | Process for preparation of 1-h-imidazo (4,5-b)pyrazin-2-ones |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
AU2001248701A1 (en) | 2000-03-24 | 2001-10-03 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US20050119305A1 (en) | 2001-03-21 | 2005-06-02 | Masao Naka | Il-6 production inhibitors |
US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
JP2005507419A (ja) | 2001-11-01 | 2005-03-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | グリコーゲン合成酵素キナーゼ3ベータ阻害剤としてのアミド誘導体 |
PL213783B1 (pl) | 2002-03-13 | 2013-05-31 | Janssen Pharmaceutica Nv | Podstawiona pochodna piperydyny lub piperazyny, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna |
ATE396971T1 (de) | 2002-03-13 | 2008-06-15 | Janssen Pharmaceutica Nv | Sulfonylaminoderivate als neue inhibitoren von histondeacetylase |
US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
EP1608628A2 (en) | 2003-03-17 | 2005-12-28 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
AP2157A (en) | 2003-07-24 | 2010-09-13 | Basf Ag | 2-substituted pyrimidines. |
DK1673349T3 (da) | 2003-09-22 | 2010-10-25 | S Bio Pte Ltd | Benzimidazolderivater: fremstilling og farmaceutiske anvendelser |
WO2005030705A1 (en) | 2003-09-24 | 2005-04-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
AU2005230682B2 (en) | 2004-04-05 | 2010-10-21 | Merck Hdac Research, Llc | Histone deacetylase inhibitor prodrugs |
US20080182865A1 (en) | 2005-03-11 | 2008-07-31 | Witta Samir E | Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
EP2491926B1 (en) | 2005-03-22 | 2018-05-09 | President and Fellows of Harvard College | Treatment of protein degradation disorders |
GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
JP2009509923A (ja) | 2005-08-26 | 2009-03-12 | メシルジーン、インコーポレイテッド | ヒストンデアセチラーゼのベンゾジアゼピン及びベンゾピペラジン類似体阻害薬 |
ES2384182T3 (es) | 2005-11-01 | 2012-07-02 | Sumitomo Chemical Company, Limited | Proceso para la producción de 6,6-dimetil-3-oxabiciclo[3,1,0]hexan-2-ona |
MX2008010035A (es) | 2006-02-07 | 2008-10-17 | Astellas Pharma Inc | Compuestos de n-hidroxiacrilamida. |
WO2008091349A1 (en) | 2006-02-14 | 2008-07-31 | The President And Fellows Of Harvard College | Bifunctional histone deacetylase inhibitors |
CA2654540C (en) | 2006-05-03 | 2017-01-17 | President And Fellows Of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
US20100278782A1 (en) | 2006-06-12 | 2010-11-04 | Vrije Universiteit Brussel | Differentiation of rat liver epithelial cells into hepatocyte-like cells |
ES2288802B1 (es) | 2006-07-07 | 2008-12-16 | Universidad De Granada | Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas. |
KR101433629B1 (ko) | 2006-09-11 | 2014-08-27 | 쿠리스 인코퍼레이션 | 아연 결합 부분을 함유한 티로신 키나아제 억제제 |
CN101573333B (zh) | 2006-10-28 | 2013-06-12 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
CA2672270A1 (en) | 2006-12-15 | 2008-06-26 | Gennadi V. Glinksy | Treatments of therapy resistant diseases and drug combinations for treating the same |
US8518979B2 (en) | 2007-02-21 | 2013-08-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Alpha-halo- and alpha-alkyl-cyclopropylcarboxy compounds and uses thereof |
KR101325374B1 (ko) | 2008-02-19 | 2013-11-08 | 가부시키가이샤 오츠까 세이야꾸 고죠 | 신체 기능의 회복에 유용한 경구 또는 경장 조성물 |
US20110182888A1 (en) * | 2008-04-08 | 2011-07-28 | Peter Ordentlich | Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator |
WO2009137462A2 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
WO2009137503A1 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Hdac inhibitors and uses thereof |
AU2009271019A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
WO2010011296A2 (en) | 2008-07-23 | 2010-01-28 | President And Fellows Of Harvard College | Deacetylase inhibitors and uses thereof |
EA024252B1 (ru) * | 2009-01-08 | 2016-08-31 | Кьюрис, Инк. | Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой |
US8716326B2 (en) | 2009-05-15 | 2014-05-06 | Korea Research Institute Of Chemical Technology | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same |
WO2011011186A2 (en) | 2009-07-22 | 2011-01-27 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
US20130040998A1 (en) | 2010-01-08 | 2013-02-14 | Dana-Farber Cancer Institute, Inc. | Fluorinated hdac inhibitors and uses thereof |
TWI511732B (zh) | 2010-01-22 | 2015-12-11 | Acetylon Pharmaceuticals Inc | 作為蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法 |
AU2011239537A1 (en) * | 2010-04-16 | 2012-11-15 | Curis, Inc. | Treatment of cancers having K-ras mutations |
US8513421B2 (en) * | 2010-05-19 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
AU2011255281A1 (en) | 2010-05-21 | 2013-01-10 | Sloan-Kettering Institute For Cancer Research | Selective HDAC inhibitors |
WO2012018499A2 (en) * | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
CA2818125A1 (en) * | 2010-11-16 | 2012-05-24 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
WO2012083243A1 (en) * | 2010-12-16 | 2012-06-21 | Massachusetts Institute Of Technology | Rnai based method of screening and characterizing drug combinations |
EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
WO2013013113A2 (en) * | 2011-07-20 | 2013-01-24 | The General Hospital Corporation | Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
WO2013158984A1 (en) | 2012-04-19 | 2013-10-24 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
WO2014059306A1 (en) | 2012-10-12 | 2014-04-17 | The Trustees Of The University Of Pennsylvania | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
NZ744567A (en) * | 2012-11-01 | 2020-03-27 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
JP2016511237A (ja) | 2013-02-01 | 2016-04-14 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | 選択的hdac3阻害剤 |
US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
EP3004141A4 (en) | 2013-06-03 | 2017-05-31 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase ( hdac) biomarkers in multiple myeloma |
JP6626437B2 (ja) * | 2013-10-08 | 2019-12-25 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | ヒストンデアセチラーゼ阻害剤とHer2阻害剤またはPI3K阻害剤のいずれかの組み合わせ |
WO2015054355A1 (en) * | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma |
ES2862126T3 (es) * | 2013-10-10 | 2021-10-07 | Acetylon Pharmaceuticals Inc | Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa |
JP2016536354A (ja) * | 2013-10-10 | 2016-11-24 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | 非ホジキンリンパ腫を治療するための、hdac阻害剤単独またはbtk阻害剤との組み合わせ |
US20150105358A1 (en) * | 2013-10-11 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
EP4137135B1 (en) | 2013-10-24 | 2024-06-05 | Mayo Foundation for Medical Education and Research | Treatment of polycystic diseases with an hdac6 inhibitor |
CR20160308A (es) * | 2013-12-03 | 2016-11-08 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores |
WO2015095632A1 (en) * | 2013-12-20 | 2015-06-25 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma |
US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
US20150359794A1 (en) | 2014-06-13 | 2015-12-17 | Buck Institute For Research On Aging | Impairment of the large ribosomal subunit protein rpl24 by depletion or acetylation |
CN107205988A (zh) * | 2014-07-07 | 2017-09-26 | 埃斯泰隆制药公司 | 利用组蛋白脱乙酰酶抑制剂治疗白血病 |
EP3204006A4 (en) | 2014-10-08 | 2018-04-04 | Regenacy Pharmaceuticals, LLC | Induction of gata2 by hdac1 and hdac2 inhibitors |
AU2015356779A1 (en) | 2014-12-05 | 2017-07-13 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma |
WO2016090230A1 (en) | 2014-12-05 | 2016-06-09 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds for treating peripheral neuropathy |
SG11201704759QA (en) | 2014-12-12 | 2017-07-28 | Regenacy Pharmaceuticals Llc | Piperidine derivatives as hdac1/2 inhibitors |
US11813261B2 (en) * | 2016-04-19 | 2023-11-14 | Acetylon Pharmaceuticals, Inc. | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia |
-
2014
- 2014-10-06 JP JP2016521347A patent/JP6626437B2/ja active Active
- 2014-10-06 EP EP14851657.8A patent/EP3054952B1/en active Active
- 2014-10-06 WO PCT/US2014/059238 patent/WO2015054099A1/en active Application Filing
- 2014-10-06 ES ES14851657T patent/ES2929576T3/es active Active
- 2014-10-06 US US14/506,889 patent/US9403779B2/en active Active
-
2016
- 2016-06-22 US US15/189,554 patent/US10722512B2/en active Active